Celltrion Healthcare IPO finally lifts off

The sales arm of drug maker Celltrion kicks off Korea's largest share sale this year hoping to match the success of other recent biopharma deals.
Celltrion Healthcare counts Remsima sales as its main revenue source.
Celltrion Healthcare counts Remsima sales as its main revenue source.

South Korea's Celltrion launched the domestic investor roadshow for a delayed W1 trillion $881 million initial public offering of its sales and distribution division on Monday, hoping to capitalise on robust investor sentiment towards biopharmaceutical IPOs.

Sources familiar with the situation said Celltrion Healthcare, which is headquartered in Incheon, has also begun to gauge interest from international investors ahead of an international roadshow starting July 3. Drugs group Celltrion aims to list the business on Kosdaq by August-end.

The start of the domestic investor roadshow marks an end to the recent saga surrounding Celltrion Healthcare's accounting practices. Celltrion Healthcare had intended to...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222